Q3 2025 Organon & Co Earnings Call
Speaker #1: After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, please press star 1 on your telephone keypad.
Speaker #1: I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations. You may begin.
Speaker #2: Thank you, Operator, and good morning, everyone. Today, we will be referencing a presentation that is visible during this call for those of you on our webcast.
Speaker #2: This presentation will also be available following this call on the events and presentations section of our Organon & Investor Relations website. Please reference slides 2 and 3 for some brief reminders.
Speaker #2: I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as "potential," "should," "will," "continue," "expects," "believes," "future," "estimates," "believes," and other words of similar meaning.
Speaker #2: Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings, with the SEC.
Speaker #2: This includes our most recent Form K and Forms 10Q, and those amended forms that we filed earlier this morning, as well as our October 27th, 2025 Form 8K.
Speaker #2: These statements are based on information as of today, November 10, 2025, and, as required by law, Organon undertakes no obligation to update or revise any of these forward-looking statements.
Speaker #2: In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP.
Speaker #2: Descriptions of these measures and reconciliations to the comparable GAAP measures are included in today's earnings press release and conference call presentation, both of which are available on our Investor Relations website, and have been furnished to the SEC on a current report on Form 8K.
Speaker #2: I note that while our full year 2025 guidance measures other than revenue are provided on a non-GAAP basis, Organon does not provide GAAP financial measures on a forward-looking basis because we cannot predict with reasonable certainty and without unreasonable effort the ultimate outcome of those legal proceedings, unusual gains, and losses the occurrence of matters creating GAAP tax impacts and acquisition-related expenses.
Speaker #2: These items are uncertain, depend on various factors, and could be material to our results, computed in accordance with GAAP. On the call today, Carrie, Joe, and Matt will address certain information about our internal investigation.
Speaker #2: Additional information about the investigation is available in our SEC filings. Beyond their statements today and the information in our filings, we will not be taking questions on the investigation.
Speaker #2: Today, the team will discuss our business 3rd quarter results and guidance, and they will take questions on those matters after they're prepared remarks. And now I'll turn the call over to Carrie.
Speaker #3: Thank you, Jen. Hello, everyone, and thank you all for joining us today. I've had the privilege of serving as board chair of Organon since 2021.
Speaker #3: I've been in the farm industry now over four decades, and about half of those years were spent in global leadership roles, which required navigating businesses through periods of transformation and growth.
Speaker #3: A good part of that experience was leading shearing plow global pharmaceuticals until the merger with Merck. So I have a deep understanding of many of our products and markets here at Organon.
Speaker #3: Since Organon's inception, our mission has been to deliver impactful medicines and solutions for a healthier every day. There is a shared passion at Organon to advance the complete health of women at all stages of her life, and that's what drew me to Organon from the beginning.
Speaker #3: While we focus on women's health, we also have a diverse portfolio of biosimilars and established brands that are important in markets around the world.
Speaker #3: I'm here today because I have assumed a new role at Organon as Executive Chair. Following the board's investigation, into the company's improper sales practices with two distributors with respect to U.S.
Speaker #3: sales of Nexplanon. I will be supporting Joe Morrissey, who I will speak about in a minute, as our interim CEO. The board has formed a search committee, and we'll be conducting a search for our permanent CEO.
Speaker #3: In this role, my focus will be on working closely with our leadership team to ensure that we align our resources to our highest priorities and drive operational performance across the portfolio.
Speaker #3: I will be deeply engaged in monitoring progress, addressing challenges quickly, and ensuring that every part of the business is working towards our shared goals.
Speaker #3: The independent, internal investigation relating to the company's Nexplanon sales to wholesalers in the U.S. is complete. And our remediation efforts are underway, including enhanced controls, certain personnel actions, additional training, and expanded written procedures.
Speaker #3: The company's wholesaler sales practices identified through this investigation have ceased. And we have new leadership at the company and in our U.S. commercial sales area to ensure this does not happen again.
Speaker #3: The board and I are confident that Joe is the right person to assume the role of interim CEO of Organon and to oversee the remediation measures.
Speaker #3: He brings integrity, a strong focus on operational excellence, and a deep commitment to executing our strategy. Joe came to Organon from Merck, where he spent more than 30 years.
Speaker #3: At Organon, he was already a member of the executive leadership team and has served as head of global manufacturing and supply chains since Organon's inception, leading the company's efforts to deliver medicines and solutions around the world.
Speaker #3: We appreciate Joe agreeing to step in at this critical juncture. Importantly, I want to stress that our drive for operational excellence and meeting our goals to move our company forward into the future remains unchanged.
Speaker #3: With that said, I'll hand it over to Joe so that he can talk a bit about his and Organon's strategic priorities.
Speaker #4: Thank you, Carrie. I appreciate the introduction and the opportunity to speak with everyone today. As Carrie mentioned, I spent more than three decades at Merck, where I led a number of manufacturing businesses as well as corporate strategy.
Speaker #4: That experience, combined with my deep understanding of our products, our markets, and our supply chains, made joining Organon a natural step as I was excited to build something meaningful from the ground up, leveraging our strong history.
Speaker #4: We have faced many challenges in these first four and a half years, but we have a resilient and capable global team. Our diverse product portfolio and footprint help us to generate meaningful revenue and deliver real value to patients and communities around the world.
Speaker #4: As Carrie has said, our strategic priorities have not changed. Moving forward, we remain focused on executing against these priorities. As we've previously shared, these include deleveraging the business, driving cost savings, and achieving revenue growth.
Speaker #4: I am, I believe, deeply in Organon's mission, our values, and our people around the world. I'm fully committed to helping Organon succeed. And with that, I hand it over to Matt.
Speaker #5: Thank you, Joe. Beginning on slide four, 3rd quarter revenue was $1.6 billion, and adjusted EBITDA was $518 million. Representing an adjusted EBITDA margin of 32.3%.
Speaker #5: Before I go deeper into a discussion of Q3 results, I'd like to spend a minute walking through some specifics about the company's U.S.
Speaker #5: wholesaler sales practices to carry reference. It's important that investors understand this issue properly. There is limited revenue impact and no financial restatement is necessary.
Speaker #5: All revenue was properly recorded in accordance with U.S. gas. On slide five, you'll see a summary of the revenue impact from these practices for the recent quarterly periods identified by the investigation.
Speaker #5: The revenue that we're highlighting is that of Nexplanon sales to two U.S. wholesalers with specific emphasis on revenue transactions occurring close to quarter end.
Speaker #5: Certain revenue transactions were advanced or pulled forward into the current quarter in excess of estimated patient demand and/or contractually agreed inventory holding levels. For example, for the 3rd quarter of 2024, on the left-hand side of this chart, the sales practices in question resulted in approximately $5 million of pull-forward revenue from the 4th quarter of that year.
Speaker #5: In the 4th quarter of 2024, there was approximately $15 million pulled forward from the 1st quarter of 2025. So the net impact in the 4th quarter of 2024 was $10 million.
Speaker #5: Importantly, because we're talking about the pull-forward of sales, these quarterly numbers are not cumulative. Our financial statements have been consistently reflecting the net impact which is clearly not material to our consolidated revenue.
Speaker #5: Three other important points to make here. First, revenue recognition in all cases was appropriately recognized in accordance with U.S. gap, specifically Section ASC 606.
Speaker #5: Two, during these periods, product returns were at or below historical levels. And three, in every relevant period, the units that were pulled forward occurred late in the 3rd month of that quarter, and were absorbed through patient demand by approximately the end of the 1st month of the following quarter.
Speaker #5: Since this practice has ceased and will not continue in the future, we will see the most significant impact in the fourth quarter of this year because the $17 million pull-forward in Q3 2025 will not have an offsetting buy-in in Q4 2025.
Speaker #5: As a result, the pull-forward dynamic rolls off in the fourth quarter and will be contained within the 2025 fiscal year, with no carryover impact to 2026.
Speaker #5: One last point on this topic. In the 8K filing on October 27th, the financial impact of these practices for the relevant periods was described as being less than 1% of consolidated revenue for the full year of 2022 and full year of 2024, and less than 2% of consolidated revenue for the relevant quarterly periods.
Speaker #5: Subsequently, we have completed our testing and detailed reviews, resulting in the more narrow estimates that you see here on slide five, which are clearly within the range as disclosed in the 8K.
Speaker #5: Now, moving to a discussion of 3rd quarter 2025 results. To be clear, when I refer to revenue and revenue variances, unless otherwise noted, those references are to revenue recorded in our financial statements without adjusting to back out the pull-forward.
Speaker #5: So let's go franchise by franchise, and then we'll move to a discussion of revenue by driver. So turning to slide six, the women's health franchise declined 4% in a constant currency in the 3rd quarter of 2025 compared with the 3rd quarter of 2024, with growth in contraceptives marvel on Mersalon and NuvaRing partially offsetting a 9% decline in Nexplanon at constant currency.
Speaker #5: Global Nexplanon sales in the 3rd quarter were $223 million. In the U.S., Nexplanon declined 50%, while internationally, the product grew 7% ex exchange. The biggest challenge facing Nexplanon this quarter was unfavorable U.S.
Speaker #5: policy, which emerged in Q2, accelerated in Q3, and had the biggest impact in the budget constrained public segments. Planned Parenthood and federally qualified health centers.
Speaker #5: Where Nexplanon has a leading market share among long-acting reversible contraceptives. In Q2, we cited U.S. policy decisions that impact Title X funding and Planned Parenthood.
Speaker #5: In the 3rd quarter, formalization of these policies intensified budget and access constraints, with the greatest impact being realized in Planned Parenthood. On the commercial side, our Nexplanon business is primarily comprised of integrated delivery networks, and to a lesser extent, independent healthcare clinics.
Speaker #5: In the independent commercial clinics, we've seen a shift away from bulk purchasing, or buy and bill, towards single unit specialty pharmacy fulfillment of these claims, as these small businesses try to preserve cash.
Speaker #5: This is also largely macro-driven, and related to inflationary and economic factors that independent healthcare clinics are facing. We see these headwinds persisting in the 4th quarter in the U.S., and likely to result in full year U.S.
Speaker #5: Nexplanon sales that are down mid to high single digit for the full year. We expect international sales of Nexplanon to grow mid to high single digits XFX this year.
Speaker #5: Putting that together, that means we expect global Nexplanon sales will be down low single digit in 2025 compared with full year 2024 on an ex exchange basis.
Speaker #5: In the 4th quarter, that implies global Nexplanon sales will be down by mid-teens ex exchange, compared with the 4th quarter of 2024. The discontinuation of the wholesaler practices I mentioned will likely explain about two-thirds of the year-over-year variance in the 4th quarter.
Speaker #5: Turning to other components of our women's health business. Our fertility business was flat in the 3rd quarter, and up 13% year to date XFX.
Speaker #5: For the full year, we expect high single digit growth, driven by the U.S., which represents about 40% of our global fertility business, as well as market expansion outside the U.S.
Speaker #5: And rounding out women's health, on November 6th, we announced that Organon has entered into a definitive agreement to divest the JADA system for $440 million plus another $25 million contingent on 2026 revenue targets.
Speaker #5: Since acquiring JADA four years ago, the JADA team successfully launched the product in the U.S., secured approvals across multiple countries, and managed design iterations as part of continuous improvement activities, all leading to JADA being recognized as the standard of care in postpartum hemorrhage management.
Speaker #5: With this divestiture, Organon can deliver faster by applying the proceeds to debt reduction, and put JADA in the hands of a medtech company well positioned to build on our great work and the very successful launch of the product.
Speaker #5: Turning now to biosimilars on slide seven, year-to-date performance is largely driven by head LIMA, which is up 63% XFX globally through September, and continues to rank among the leading biosimilars in terms of total prescriptions in the U.S.
Speaker #5: This performance reflects the strong clinical profile of head LIMA, which includes the recent interchangeability approval in the U.S. Head LIMA has also benefited from the effectiveness of our low-price strategy, as well as expansion into Canada and Puerto Rico.
Speaker #5: The 3rd quarter also benefited from an international tender for Atrosant, meant to a lesser extent, contribution from our new Denosumab biosimilar, which was approved by the FDA and launched in the U.S.
Speaker #5: in late September, and Tofodence, which the company acquired in the 2nd quarter of 2025. Wrapping up the franchise discussion with established brands now on slide eight.
This is an improvement over our prior range of 155 to 185 million.
Volumes increased 70 million in the third quarter representing growth of about 4.5% driven by the addition of the Tama to the portfolio. Continued growth in mgal and style of performance have had Lima.
Given year-to-date performance and our view into the fourth quarter, we estimate that volume could grow about 2.5% for the full year 2025, a revision from our former estimate of 6% to 7%.
This would imply low single-digit decline in the fourth quarter and is reflective of continued softness. In the respiratory portfolio. Persisting policy headwinds in the U, in us, nexplanon and a flatter than expected ramp of vitamins.
In Supply other here, we capture the lower margin contract, manufacturing Arrangements that we have with Merc, which have been declining since the spin-off as expected.
and lastly, foreign exchange translation had an approximate 40 million, favorable impact in the quarter, or about 200 basis points, which reflects the weaker US dollar versus the majority of foreign currencies, in which we transact,
For the full year. We now expect the impact for FX to represent about a 50 to 70 basis, point Tailwind, total revenue.
Items and metrics for the quarter for reference Gap financials. And reconciliations, to the non-gaap financial measures are included in our press release and the slides in the appendix of this presentation.
For gross profit. We are excluding purchase accounting amortization and 1-time items from cost of goods sold which can be seen in our appendix slides.
Adjusted gross margin was 60.3% for the third quarter compared with 61.7% in the third quarter of 2024.
This year-over-year decline in the non-gaap adjusted, gross margin is. Primarily attributable to pricing pressure on favorable product mix
And unfavorable foreign exchange on our inventory turns.
Adjusted even to this quarter was 518 million representing a 32.3% margin.
Year to date adjusted, even a margin is running favorable in part based on the timing of sg&a spend.
There are planned increases in our SG&A spend in the fourth quarter, as we support growing products such as Vtama and To Finance.
Year-to-date non-GAAP SG&A as a percentage of sales is 25.4%, and given the investments I just mentioned, our latest estimate is about half a point higher than that for the full year.
Starting to free cash flow on slide 11.
Year to date, we've delivered 813 million of free cash flow before 1-time costs.
1-time costs related to the spin-off were completed in 2024 following the roll out of our globally, RP system, what remains are margin, enhancing restructuring and Manufacturing separation activities for 2025 which were 244 million year to date in line with our expectation of 250 to 300 million for the full year.
Year to date. These breakout as follows approximately 100 million dollars, relates to cash payments associated with the restructuring initiatives that were executing to deliver $200 million of operating expense savings this year.
The $20 million relates to the final payment on the microspheres legal settlement.
And the remaining $120 million relates to the planned exits from supply agreements with Merc.
These are activities that will enable organon to redefine our appropriate sourcing strategy and move to fit for purpose Supply chains. While focusing on delivering efficiencies in terms of gross margin expansion, which we expect to begin realizing in 2027.
Below the free cash flow line, our estimate of Business Development. Cash Investments for 2025 is approximately 240 million related to contractual milestones for vtama mgal and the biosimilar programs with Shanghai henlius.
Through the first 9 months of the year, the majority of those payments have already been made.
Turning out to leverage on slide 12. Net leverage as of September 30th was approximately 4.2 times down from 4.3 times at June 30th.
Earlier in the year, we took action to realign our capital allocation priorities and target a net leverage ratio of below 4 times. To that end, in the second quarter, we repaid approximately $350 million in principal of long-term debt instruments.
As I mentioned once the Jada transaction closes which we estimate will be q1 of 2026, we will apply the net proceeds after taxes, and transaction costs to lowering our debt balance as well.
Given our revised guide. We will likely end the year in line with Q3 with proceeds from the Jada sale. Helping to move the needle on Leverage in early 2026.
Now, turning to 2025, full year revenue guidance on slide 13.
Given year-to-date performance and risk, adjusting the fourth quarter. For what we see is persisting us policy. And next ban on and the challenges in the respiratory business. We're lowering our full year range to 6.2 billion to 6.25 billion, from 6.275 billion to 6.375 billion dollars, which represents a year-over-year nominal decline of 3.2 to 2.4% negative.
Given the approximate 35 to 45 million Tailwind. We expect from FX for the full year. That means we're revising. Our constant currency Revenue. Guide down about 300 basis points at the midpoint,
We continue to expect the adjusted gross margin to be in the range of 60% to 61%.
Year-to-date strength and adjusted. Gross margin is likely to be partially offset in the fourth quarter due to product mix.
Venue to be about half a point higher than the year-to-date figure which puts us in the 26% area for the full year.
We continue to expect R&D as a percentage of sales to be in the upper single digit range.
The math on all those components gets you closer to the lower end of the 31 to 32%, adjusted. Even a margin range, we laid out in August of this year. So we are revising our adjusted even a margin to approximately 31% for the full year.
For below the line items, our estimate for full year 2025 interest expense remains at $510 million. The lower interest expense from voluntarily retired debt is essentially fully offset by higher Euro-denominated interest expense due to FX translation and an acceleration of non-cash amortization of capitalized fees related to the early debt retirement.
As we think about next year, we would expect interest expense to be closer to a 450 to 475 million run rate, as a result of the voluntary debt repayments completed, lower variable interest rates and applying the net proceeds from Jada to debt repayment.
For 2025, we continue to estimate, our non-gaap tax rate to be in the range of 22.5 to 24.5%.
The uptick from 2024 is largely due to the impact of the 15% Global minimum tax rate required under the oecd's pillar 2.
Depreciation of 135 million remains our estimate for the full year. 2025
At a very high level next year, proforma for the Jada destitute. We would expect Consolidated Revenue to be about flat as vama and gallaty and bio similar as growth offset the headwinds across the respiratory portfolio.
For next, bonan assuming existing headwinds in the US don't worsen and factoring in the volume and price variables associated with a 5-year launched in the US and continued. Growth internationally. We expect Global next level on revenues could be about flat next year.
We remain confident in our ability, to continue to deliver the balance sheet through disciplined expense management and prudent, Capital allocation, all of which will strengthen organized financial position and support greater Financial flexibility in the future.
Importantly, even in a challenging environment, our diverse portfolio continues to generate strong, cash flows, and provides a solid foundation for long-term value creation. We are committed to navigating the current headwinds investing behind our growth drivers and delivering for patients, customers and shareholders. And finally, while the issue raised around certain of the company's wholesaler, sales practices is receiving. A lot of focus. The financial impacts are small, remediation is well underway and as an organization, we are moving forward.
With that operator, let's open the line for questions.
Thank you. If you would like to ask a question, please press star 1 on your telephone keypad, if you would like to withdraw your questions simply press star 1. Again, please ensure that your phone is not on mute when called upon
We ask that you please limit yourself to 1 question and 1, follow-up. Thank you.
Your first question comes from Jason Gerber with Bank of America. Your line is open.
Oh, hey guys. Uh, thanks for taking my questions. Um, uh my my question is mainly, you know, given the the data that have Este are are there opportunities within the portfolio, uh, for additional divestitures, you know, as as you look across and then
As my follow-up just on on vtama uh appreciate the updates you know as it pertains to um the growth Dynamics into your end. Um, you know, when, when should we start thinking about a growth inflection? Do you feel like next year, when when the access barriers improve that at 2026 is the time point to really evaluate whether or not the the growth inflections achieved at the 80 label. Thanks
Uh, that the best teacher was the right, uh, was the right answer in that case. But that is the kind of rigor that will put a cross. All the Assets in our portfolio.
Uh, and as regards Bama Bama, um, has grown nicely this year will grow, uh, will grow again. Uh, next year to your point, we have, um, we have made significant strides to improve access in 2026 and so I think fully year 2026 will be a, a very good basis for us to be judging, um, you know, where we are, uh, on the growth trajectory, um, to achieving long-term Peak revenue of that roughly half a billion dollars, uh, that, uh, that underpin the investment for us in the first place. So, yes, 2026 will be a key year.
Yeah, thanks.
The next question comes from David Anselm with Piper Sandler. Your line is open.
Um, thanks. So a couple for me. Uh, firstly. Um, can you talk more about the pressure on respiratory? Um, and should we think of this long term as, uh, declining business. Not just 26, but, but beyond and then, secondly, how are you thinking about? You know, other potential trouble spots, trouble spots. I just say regarding, um, established brands
So that's number 1. Um, and then number 2 is on the Tama. Um, just wanted to get, um, your thoughts on, uh, competitive. Um, Dynamics here. Um, is there anything you feel like you're missing, uh, regarding, uh, the topical landscape? Um, these the, um, the RAF product in particular, um, and how we should think about that, and how that plays into your thinking regarding the product. Thank you.
Sure. So we'll start with the respiratory piece of your question, David. So, um, in the early part of the year, we were noting that the allergy season, specifically in the Asia-Pacific region, including China, was off to a very slow start. That put a dent in our thinking about the full year performance of the respiratory business. Um, but then...
As the year progressed, you know, we we were noting that competitively speaking, um, the age of certain products in the respiratory portfolio was working against them, um, various health ministries around the world were starting to prioritize other molecules above, for example, singular.
Um, and then elsewhere in the portfolio, thinking about dholera, we talked about that in the prepared comments. In terms of the rate pressures that product is facing, uh, in the United States and then rounding it out. Just mandatory price Downs in China and Japan. And also just around the world, hit that business pretty hard this year. So, as we said, we expect that uh, softness to continue into 2026 will see what sort of allergy season we have. But some of the other Dynamics I've spoken about are more longer term in nature. Um, apart from that, the rest of the established Brands portfolio is showing the stability that those products have demonstrated over long periods of time. But we've always said about these established Brands business. It is a business that you know we felt if managed very tightly we could keep about flat or maybe very very
Very low single digit rate of rate of decline that is not a kegger basis, some years will be different than others, we've we've added to the established Brands portfolio. Having a global commercial infrastructure like we do is an asset. So products like emgality tucked in very nicely and in Galilee continues um, to grow and now the Wave 2 markets now that we've added them. Um, I think are uh, case in point for what we
We can do with the infrastructure that, uh, that that uh, that we have.
So, no other trouble spots that we are um, that we're managing uh, at the, uh, at the moment.
Comments is really, um, differentiated in terms of no drug to drug interactions. No restrictions on use. Um, no limitations on a percentage of, uh, of uh, of body are. So it's a very safe product and we're looking to differentiate it with the, those patients for whom those. Those characteristics are very important including Pediatrics.
Um,
So okay, next question, please.
The next question.
For Rapid.
SI your line is open.
Morning guys, I wanted to start by commending you for getting the 10 Q out. Um but I realized we haven't been able to speak at all since the inventory disclosures a few days ago. So I feel like it's only fair that we don't limit to just 1 question. So here's here's what I wanted to address on this public call first. Um, the audit committee investigation focused on Max, ban on how do we know that the behavior was just limited to an exponent because inventory visibility is always lower xus. So, how do we know second, um, the filings point to the CEO and the head of us commercial, um, as where the um, Divergence happened, but I also saw your Chief commercial officer left back in February last this year, as well. Why was that third? Um, for 2024 your net pull forward is only 10 million but the discounts and rebates paid to the channel went up by 177 million and 24, which puzzles me.
So could you elaborate on that? Um, additionally 4 q202 had some inventory as well, but I didn't see any color on that and then finally um the scale of these issues seems uh fairly low fairly manageable 1015 million sub, 20 million. But if that's the case, then why the need to start this to best your plan? Thank you very much.
You be careful with a couple of things Boomer. So as I mentioned in my comments, uh, the independent internal investigation around the uh improper sales practices with an exponent in the US was with 2 who wholesalers and it's now complete
Uh, the investigation also looked through other product areas and found nothing else at this time. So we believe that we are done with the investigation now and we're moving forward into the remediation efforts. And again, as I mentioned that's things like enhancing our controls. We have taken certain Personnel actions. We believe that's completed. We're doing additional training and we've got, you know, more written procedures and more training yet to come. So, with the new leadership at the company, we're comfortable that we're moving forward and we will continue to execute against our goals as stated Matt. Do you want to take the other? Yeah. So, um, for the, uh, for the next, but on, uh, piece as we stated in the, uh, prepared commentary, uh,
Uh, Omar, the marketplace for long-acting reversible contraceptives has gotten more competitive.
And so we are meeting that competition partially on price, so that would result in some of the increases in rebates and discounts that you noted. This is just, I would say, normal business. And next, on operating in a competitive marketplace where women have lots of options for contraception.
and on the cute for 2022.
we didn't it wasn't on our slide, but
Female.
This is closed in the 10K. Yeah, 222 um umer you had a number of uh other other questions. I just want to make sure we get to them all.
Can you repeat the ones that you don't think we've answered yet?
Yeah, sure, maybe more, um, more q22 that wasn't disclosed. Also, the chief commercial officer who left separate from the head of w. Why was that? And then, why do all the devest shares now?
Oh, so, uh, for Q4 of, uh, 2022. Um, the uh, the uh, the, um, the revenue was uh, impacted. But I, I think it was about 1.15, 1.5, um, percent on the quarter, 0.3% for the year.
And uh, the destitutes, I I think we've already uh, addressed that, uh, Uber. We had an opportunistic chance to uh, divest an asset for which the economic value. Uh, received on an immediate basis was what was superior to the hold and invest option.
Ends. Um, not tied to the investigation anyway.
Thanks Sumer.
The next question.
Thank you. The next question comes from Chris shot of JP Morgan. Your line is open.
All right. Great dad. Thanks very much. Um, just 2 questions for me. Um, maybe Carrie, can you just talk a little bit about the new CEO search and kind of, what's the optimal background and profile? You're looking for here and it's part of either the search or with the new CEO coming in. Should we assume a review of the broader strategy at organ on as part of this process? And then my my fault but just on next. But on um thank you for the comments about the flat growth next year just can you all have a little bit more in what that in terms of what that implies for these funding challenges and the impact of the 5 year launched on on the US Revenue. Thanks so much.
Thanks, Chris. The board formed a search committee essentially immediately this week, and the committee has been hard at work. We are in the process of conducting that search, and like any company at this point, we need someone who has the global experience, the strategic experience, the operational depth, and a deep understanding of the businesses in which we operate. So we're confident that we not only have a great interim CEO, but we will continue to find good candidates as we go forward.
I think the strategic discussion obviously waits for a permanent CEO, but at this point we've been reaffirming that we don't see any strategic changes. So I would say we are what we are right now, and we intend to continue that way and are very much focused on driving towards our goals.
And I'll take the second part of the question on next 1 on. So, in terms of our current view, next 1 on being about flat next year, the components of that, we expect the product to continue to grow internationally.
From a policy perspective, assuming things don't get any worse. What we would probably see is an annualization of the issues that we experienced in the second half. Um, and then the 5 year, which um, you know, we're we uh, we are assessing the relative weighting of the impacts of volume growth as the product, would be appealing to a larger segment of the addressable population with a 5 year indication versus 3.
The volume, um, uh, decline that would come from, um, lower reinsert, right? As women, who would be coming up to the 3 year limit, can leave the rod in their arm now for longer and then uh what we're able to do on the pricing front. So we'll have all of this uh sorted out more precisely when we guide in February but
But these are the things, uh, Chris, that would be pushing and pulling, uh, on the overall belief that Revenue will be about flat next year.
The next question comes from Terrence Flynn with Morgan Stanley, your line is open.
Hi, thanks for taking the questions. Uh, I was just at 1 follow up on the CEO. Search was wondering if you can speculate on the duration of the search. When you hope to have, uh, someone in place, um, on a permanent basis and then on, um, the NASA map on that product, um, obviously 1 of your newer, um, biosimilars that that you're launching, you know, Amgen is expressed a lot of optimism about maintaining, uh, more share on the Prius side versus xja. Can you just talk through your expectations, um, for fourth quarter but then also, um, into 2026. Thank you.
So, on timing of the CEO search, you know, it's always impossible to predict how long these things take the board did begin right away. So, I'm confident we're doing what's necessary to go as fast as we can. But we also feel very good about putting Joe in, as our, pardon me, as our interim CEO and I stepped into assist him, along with Matt, of course. So we're confident, we can continue to run the company, well, in the interim and we'll be moving through the search as fast as appropriately. We can go.
and for all of our, uh, for all of our us, biosimilars
The next question comes from Navanti with BNP Paribas. Your line is open.
Hi, good morning. Um, I have some questions on Capital, allocation, if you could discuss the future BD in a woman's health biofarma only understand and the timing of of Business Development versus Della bridging progress.
Uh and second if you could also discuss your pipeline versus the the cost discipline strategy including lower R&D. Thank you.
Yeah, thank you, Nan. So, uh, our uh, our business development activities in women's health continue, um, to the question that you're asking, um, we just because of where the balance sheet is, we've had to focus on later stage. Uh, assets are currently marketed assets. You can see that clearly in the kinds of deals that we have announced, uh, that we've announced recently and the challenging women South is, there aren't a lot of those assets that are available late stage and currently marketed a lot of the truly exciting things, uh, in women's health are, uh, pre-clinical or generally speaking much earlier in the uh, in the development cycle. So we are somewhat constrained in our ability to go after those. And that's 1 of the reasons why we've been prioritizing, um, leverage reduction debt repayment in our Capital allocation.
Action strategies so that we can free up the ability of the balance sheet and P&L to bring on the clinical programs, especially Women's Health, that are preclinical or early stage.
Um, once again, because of the financial challenges stakes in the company, we've applied that same rigor, not just to the BD we're looking at, but also to the, uh, to the pipeline that we are managing in-house, and we've had to trim some, we've had to trim some programs. Those weren't restricted to, um, Women's Health, we've got life cycle management activities across a number of products in the portfolio. Um, but it is, you know, it's incumbent upon us to supply that same kind of financial rigor, and discipline to things inside the company as well, as any Capital. Uh, deployments we might do externally
The next question comes from Mike nadduli with TD Cowen, your line is open.
Hi. Thank you for the question. I have 1 and actually is, uh, something of a follow-up on the BD response. You just gave I think with today's updates, it's fair to say that uh, Business Development, track record is somewhat mixed. So, I'm wondering what you could do from here, to improve it, especially given how important BD is to potential growth for organon. Uh, and could that, uh, options that include expanding to therapeutic categories. Well, beyond Women's Health,
So, thank you for the question. Um, I, you know, I think we, we, we've shown success in the BD program with latter, stage assets, where we've got synergies, um, with our existing commercial capabilities,
So the the the broad strategy just doing more of what we already do. Well I think emgality is a terrific example of that.
Um, as we and uh with the addition of dermavant, we actually did already add a completely new vertical in the United States with Dermatology right now, the dermavant team. Um, that we added which is now organized. Dermatology sales force is selling just 1 product. So we would have synergies um going forward as we look to add additional Derm products to that team.
Um, and we're already in, when you look at the established brands business, we're already in a pretty broad range of therapeutic categories outside the United States. So, we believe that we've got lots of opportunities with the therapeutic areas we're already in with what we've already added with Dermavant.
So that we wouldn't necessarily need to add another therapeutic category in order to be successful with capital deployments, although we certainly wouldn't rule it out. If it capitalizes once again on some functional expertise that we already have, whether it's the global commercial network or perhaps there's something that aligns particularly well with our manufacturing capabilities, for example.
This concludes the question-and-answer session and will conclude today's conference call and webcast. Thank you for joining. You may now disconnect.